Provectus Biopharmaceuticals, Inc.
PVCT · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $307 | $77 | $22 | $683 |
| Short-Term Investments | $0 | $0 | $0 | $0 |
| Receivables | $0 | $0 | $0 | $5 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $669 | $1,288 | $1,877 | $2,754 |
| Total Curr. Assets | $977 | $1,365 | $1,899 | $3,442 |
| Property Plant & Equip (Net) | $29 | $84 | $138 | $71 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $0 | $0 | -$138 | -$71 |
| Total NC Assets | $29 | $84 | $138 | $71 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $1,006 | $1,449 | $2,037 | $3,513 |
| Liabilities | – | – | – | – |
| Payables | $1,107 | $1,676 | $2,094 | $1,287 |
| Short-Term Debt | $3,185 | $3,001 | $2,156 | $1,790 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $336 | $953 | $1,511 | $2,500 |
| Other Curr. Liab. | $2,348 | $3,387 | $2,431 | $2,123 |
| Total Curr. Liab. | $6,975 | $9,017 | $8,192 | $7,701 |
| LT Debt | $0 | $25 | $73 | $0 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $0 |
| Total NC Liab. | $0 | $25 | $73 | $0 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $25 | $73 | $118 | $46 |
| Total Liabilities | $6,975 | $9,042 | $8,266 | $7,701 |
| Equity | – | – | – | – |
| Pref Stock | $14 | $23 | $22 | $22 |
| Common Stock | $420 | $420 | $419 | $419 |
| Retained Earnings | -$257,423 | -$252,690 | -$249,589 | -$246,034 |
| AOCI | -$61 | -$60 | -$36 | -$34 |
| Other Equity | $251,090 | $244,715 | $242,954 | $241,440 |
| Total Equity | -$5,959 | -$7,593 | -$6,229 | -$4,187 |
| Supplemental Information | – | – | – | – |
| Minority Interest | -$10 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $1,006 | $1,449 | $2,037 | $3,513 |
| Net Debt | $2,877 | $2,950 | $2,208 | $1,107 |